Provides Antibe’s subsidiary, Citagenix, with resources to ramp up growth in the largest market for dental biologics
TORONTO, CANADA — (October 11, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, today announces that its subsidiary Citagenix Inc. (“Citagenix”) is launching a strategic initiative to drive growth of product sales in the U.S. market for dental biologics. Citagenix recently hired three senior-level sales directors with a wealth of industry experience who will be responsible for managing and executing this strategy.
“We are very excited to announce the addition of these deeply experienced sales professionals to the Citagenix team as we embark on our growth strategy in the United States,” said Dan Legault, Antibe’s CEO. “This initiative strengthens Citagenix’s ability to compete and grow market share in this important market, and we expect it should contribute materially to profitability in a few quarters.”
The new sales directors collectively have 65 years of experience in selling and promoting biologics and medical devices in the United States, bringing valuable customer relationships that Citagenix can leverage immediately. In addition, this new sales team will be responsible for engaging and supporting new distributors and independent representatives in key regions across the United States. The strategic initiative will also involve additional product development efforts and enhanced marketing and systems support.
According to iData Research, the U.S. market for dental bone graft substitutes and other dental biomaterials was US$341 million in 2014, representing the largest global market for oral regenerative medicine.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Contact Information
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095
[email protected]
Read all news